Industry Supported CME Satellite Symposium | Advancing the Care of Patients With CDKL5 Deficiency Disorder: Insights Into Emerging Treatments and Clinical Outcomes

Friday, December 4, 2026 at 6:00 PM to 8:00 PM · 2 hr. (America/Denver)
Industry Satellite Symposium

Information

The presentations will review CDKL5 deficiency disorder (CDD), an ultra-rare developmental and epileptic encephalopathy. The science of CDD is new and rapidly evolving, with 8 Centers of Excellence in the United States, an international database, consensus recommendations, and new treatments in development. Expert faculty will review current and emerging approaches to seizure management and elements of holistic care. A caregiver will provide insight on disease burden and meaningful improvement in CDD.

This activity is approved for AMA PRA Category 1 Credit™.

Jointly provided by Partners for Advancing Clinical Education and Miller Medical Communications, LLC.

This activity is supported by an independent educational grant from UCB, Inc.
Learning Objective 1
Identify clinical features of CDD, including types of seizure and nonseizure symptoms
Learning Objective 2
Summarize disease burden and key unmet needs of patients with CDD
Learning Objective 3
Review efficacy and safety of currently available and emerging antiseizure medications for CDD
Learning Objective 4
Evaluate the impact of antiseizure medications on nonseizure symptoms of CDD
Education Credits
1.50 AMA PRA Category 1 Credit(s)
Session ID
0
Presentation Id
3614003
Event ID
24056
Session Type
Session